Nature Communications (Sep 2022)
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
- Elisa I. Rivas,
- Jenniffer Linares,
- Melissa Zwick,
- Andrea Gómez-Llonin,
- Marc Guiu,
- Anna Labernadie,
- Jordi Badia-Ramentol,
- Anna Lladó,
- Lídia Bardia,
- Iván Pérez-Núñez,
- Carolina Martínez-Ciarpaglini,
- Noelia Tarazona,
- Anna Sallent-Aragay,
- Marta Garrido,
- Toni Celià-Terrassa,
- Octavio Burgués,
- Roger R. Gomis,
- Joan Albanell,
- Alexandre Calon
Affiliations
- Elisa I. Rivas
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Jenniffer Linares
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Melissa Zwick
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Andrea Gómez-Llonin
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Marc Guiu
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST)
- Anna Labernadie
- Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology (BIST)
- Jordi Badia-Ramentol
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Anna Lladó
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST)
- Lídia Bardia
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST)
- Iván Pérez-Núñez
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Carolina Martínez-Ciarpaglini
- Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia
- Noelia Tarazona
- Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia
- Anna Sallent-Aragay
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Marta Garrido
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Toni Celià-Terrassa
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Octavio Burgués
- Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia
- Roger R. Gomis
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST)
- Joan Albanell
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- Alexandre Calon
- Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM)
- DOI
- https://doi.org/10.1038/s41467-022-32782-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
A substantial proportion of HER2+ breast cancer patients do not benefit from HER2-targeted therapy. Here, the authors identify a population of cancer-associated fibroblasts involved in the suppression of trastuzumab-induced ADCC that can be pharmacologically targeted to raise treatment effectiveness in unresponsive tumors.
